Back to top

gene-therapy: Archive

Zacks Equity Research

EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia

The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.

LGNDNegative Net Change ANIPPositive Net Change ADMANegative Net Change RCKTNegative Net Change

Zacks Equity Research

Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development

Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.

VRTXPositive Net Change ANIPPositive Net Change ADMANegative Net Change CRSPNegative Net Change

Zacks Equity Research

REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study

Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.

SRPTNegative Net Change ADMANegative Net Change RGNXNegative Net Change SLDBNegative Net Change

Zacks Equity Research

Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.

RHHBYNegative Net Change ACETNegative Net Change SRPTNegative Net Change PBYIPositive Net Change

Zacks Equity Research

Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up

Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.

VRTXPositive Net Change ACETNegative Net Change EDITNegative Net Change AKRONegative Net Change